The effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit in diabetic kidney disease
Open Access
- 1 January 2026
- journal article
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 72 (3) , e20251460
Abstract
SUMMARY OBJECTIVE: The aim of this study was to evaluate the impact of sodium-glucose cotransporter-2 inhibitors on haematological parameters and other clinical markers in this patient population. METHODS: We retrospectively analyzed the medical records of 150 diabetic patients with chronic kidney disease who initiated sodium-glucose cotransporter-2 inhibitor therapy, comparing their baseline and 3-month post-treatment laboratory and clinical data. RESULTS: Following 3 months of treatment with sodium-glucose cotransporter-2 inhibitors, mean haemoglobin and haematocrit levels significantly increased, even in patients with an estimated glomerular filtration rate below 60 mL/min/1.73 m2. This therapy also led to significant reductions in the spot urine albumin-to-creatinine ratio, as well as in both systolic and diastolic blood pressure. CONCLUSION: Sodium-glucose cotransporter-2 inhibitor therapy was associated with significant increases in haemoglobin and haematocrit levels in diabetic patients with chronic kidney disease. These findings suggest that sodium-glucose cotransporter-2 inhibitors may represent a potential area requiring further investigation for the treatment of anaemia associated with diabetic chronic kidney disease.Keywords
This publication has 25 references indexed in Scilit:
- Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKDJAMA Network Open, 2024
- How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trialNephrology Dialysis Transplantation, 2024
- Dapagliflozin and Anemia in Patients with Chronic Kidney DiseaseNEJM Evidence, 2023
- Beneficial effects of empagliflozin on hematocrit levels in a patient with severe anemiaDARU Journal of Pharmaceutical Sciences, 2021
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine, 2020
- Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trialAmerican Heart Journal, 2020
- Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney DiseaseDiabetes Technology & Therapeutics, 2019
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019